DE69535665D1 - Konjugate enthaltend ein antitumorales mittel und deren verwendung - Google Patents

Konjugate enthaltend ein antitumorales mittel und deren verwendung

Info

Publication number
DE69535665D1
DE69535665D1 DE69535665T DE69535665T DE69535665D1 DE 69535665 D1 DE69535665 D1 DE 69535665D1 DE 69535665 T DE69535665 T DE 69535665T DE 69535665 T DE69535665 T DE 69535665T DE 69535665 D1 DE69535665 D1 DE 69535665D1
Authority
DE
Germany
Prior art keywords
bond
conjugate contains
antitumoral agent
inhibits
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535665T
Other languages
English (en)
Other versions
DE69535665T2 (de
Inventor
Andre Trouet
Roger Baurain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Region Wallonne
Katholieke Universiteit Leuven
Original Assignee
La Region Wallonne
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25662908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69535665(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from BE9400752A external-priority patent/BE1008581A3/fr
Priority claimed from BE9400751A external-priority patent/BE1008580A3/fr
Application filed by La Region Wallonne, Universite Catholique de Louvain UCL filed Critical La Region Wallonne
Application granted granted Critical
Publication of DE69535665D1 publication Critical patent/DE69535665D1/de
Publication of DE69535665T2 publication Critical patent/DE69535665T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Multicomponent Fibers (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
DE69535665T 1994-08-19 1995-08-21 Konjugate enthaltend ein antitumorales mittel und deren verwendung Expired - Lifetime DE69535665T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
BE9400751 1994-08-19
BE9400752A BE1008581A3 (fr) 1994-08-19 1994-08-19 Prodrogues, composition pharmaceutique les comprenant et leur utilisation.
BE9400751A BE1008580A3 (fr) 1994-08-19 1994-08-19 Prodrogues, composition pharmaceutiques les comprenant et leur utilisation.
BE9400752 1994-08-19
PCT/BE1995/000076 WO1996005863A1 (fr) 1994-08-19 1995-08-21 Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation

Publications (2)

Publication Number Publication Date
DE69535665D1 true DE69535665D1 (de) 2008-01-24
DE69535665T2 DE69535665T2 (de) 2009-04-02

Family

ID=25662908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535665T Expired - Lifetime DE69535665T2 (de) 1994-08-19 1995-08-21 Konjugate enthaltend ein antitumorales mittel und deren verwendung

Country Status (14)

Country Link
US (5) US5962216A (de)
EP (2) EP1880737A1 (de)
JP (2) JP4157600B2 (de)
AT (1) ATE380559T1 (de)
AU (1) AU694546C (de)
CA (1) CA2203622C (de)
DE (1) DE69535665T2 (de)
DK (1) DK0769967T3 (de)
ES (1) ES2297832T3 (de)
NO (1) NO324045B1 (de)
NZ (1) NZ291368A (de)
PT (1) PT769967E (de)
SI (1) SI0769967T1 (de)
WO (1) WO1996005863A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
DE69535665T2 (de) * 1994-08-19 2009-04-02 La Region Wallonne Konjugate enthaltend ein antitumorales mittel und deren verwendung
AU3434497A (en) * 1996-07-16 1998-02-09 Novo Nordisk A/S Oligopeptide transporters
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6127333A (en) * 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6174858B1 (en) * 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ATE460180T1 (de) 1998-12-11 2010-03-15 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
WO2001030804A2 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
WO2001068145A2 (en) * 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
WO2001091798A2 (en) * 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
EP1294404A2 (de) 2000-06-14 2003-03-26 Corixa Corporation Prodrugverbindungen mit isoleucinreste enthaltenden oligopeptiden
WO2001095945A2 (en) * 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds cleavable by thimet oligopeptidase
AU2001275525B2 (en) * 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
WO2002015700A1 (en) * 2000-08-24 2002-02-28 Coulter Pharmaceutical, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
EA006741B1 (ru) 2000-11-09 2006-04-28 Неофарм, Инк. Липидная композиция, содержащая производное камптотецина (варианты), способ её получения и применение
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
EP1355675A1 (de) * 2001-01-30 2003-10-29 Universite Catholique De Louvain Antitumorale verbindungen
GB0105929D0 (en) * 2001-03-09 2001-04-25 Btg Int Ltd Physiologically activated prodrugs
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
CA2448319C (en) * 2001-05-31 2010-07-27 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
AU2002316539C1 (en) * 2001-06-11 2008-10-30 Medarex, Inc. CD10-activated prodrug compounds
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
FR2858936A1 (fr) * 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
EP3075247B1 (de) 2004-02-02 2022-10-12 BioSight Ltd. Konjugate für die krebstherapie und -diagnose
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
JP4658507B2 (ja) * 2004-03-31 2011-03-23 竹本容器株式会社 自開式キャップ機構
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
AU2005244980B2 (en) * 2004-05-19 2011-09-15 E. R. Squibb & Sons, L.L.C. Chemical linkers and conjugates thereof
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
BRPI0607757A2 (pt) * 2005-02-18 2009-10-06 Medarex Inc anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
DK1940789T3 (da) 2005-10-26 2012-03-19 Medarex Inc Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
CA2645347A1 (en) * 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2008005942A2 (en) * 2006-06-30 2008-01-10 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. Activatable probes and methods of use
US7718044B2 (en) * 2006-09-11 2010-05-18 Seagate Technology Llc Method for controlling shaft coating taper
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
AU2008289441A1 (en) 2007-08-22 2009-02-26 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI1011384A2 (pt) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc pro-proteinas e seus metodos de uso
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
EP2922818B1 (de) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophile binder und deren verwendung zur konjugation von wirkstoffen an zellbindende moleküle
EP2781919A1 (de) 2013-03-19 2014-09-24 Roche Diagniostics GmbH Verfahren/Vorrichtung zur Erzeugung eines korrigierten Werts einer Analytenkonzentration in einer Körperflüssigkeitsprobe
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA3007065C (en) 2015-12-03 2023-02-14 Biosight Ltd. Salts of conjugates for cancer therapy
AU2016362830B2 (en) 2015-12-03 2022-07-14 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
CN106074556B (zh) * 2016-06-14 2018-11-16 河南师范大学 L型胞嘧啶丙氨酸在制备抗癌药物中的应用
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2022043256A1 (en) 2020-08-23 2022-03-03 Cobiores Nv Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
BE869485A (fr) * 1978-08-03 1978-12-01 Inst Internat De Pathologie Ce Nouveaux derives de la doxorubicine, leur preparation et les compositions qui les contiennent
US4277466A (en) 1978-08-29 1981-07-07 Institut International De Pathologie Cellulaire Et Moleculaire Complexes of DNA and esters derived from daunorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
ATE3367T1 (de) * 1978-10-02 1983-06-15 Merck & Co. Inc. Lysosomotropische therapeutische fluorierte aminverbindungen und sie enthaltende zusammensetzungen.
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
BE882541A (fr) * 1980-03-31 1980-07-16 Inst Internat De Pathologie Ce Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent
EP0037388B1 (de) * 1980-03-31 1984-12-12 Institut International De Pathologie Cellulaire Et Moleculaire Pharmazeutische Stoffe, deren Herstellung und Präparate in denen diese enthalten sind
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
OA06421A (fr) * 1980-06-10 1981-09-30 Omnium Chimique Sa Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
ATE64396T1 (de) 1983-04-29 1991-06-15 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
EP0126344A2 (de) 1983-05-20 1984-11-28 Abbott Laboratories Tripeptidester von therapeutischen Mitteln
JPS60233642A (ja) 1984-05-07 1985-11-20 Fuji Photo Film Co Ltd 写真画像の形成方法
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant
AU618029B2 (en) 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
FR2626882B1 (fr) 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
DE3841764A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5220001A (en) 1989-10-25 1993-06-15 Zaidan Hojim Biseibutsu Dong-A Pharm Co. Anthracycline glycoside derivatives
FI91777C (fi) * 1990-04-02 1994-08-10 Elomit Oy Menetelmä plasmiiniaktiivisuuden määrittämiseksi
US5618790A (en) 1990-10-05 1997-04-08 Queen's University At Kingston Protease mediated drug delivery system
KR100334696B1 (ko) 1991-08-05 2002-04-27 리차아드제이마세이 표적화된 촉매 단백질에 의해 활성화되는 선구 약제
WO1994007518A1 (en) 1992-09-25 1994-04-14 Abbott Laboratories Anaphylatoxin receptor ligands containing lipophilic residues
CA2153987A1 (en) 1993-01-14 1994-07-21 U. Prasad Kari Amino acids and peptides having modified terminals
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
DE69535665T2 (de) * 1994-08-19 2009-04-02 La Region Wallonne Konjugate enthaltend ein antitumorales mittel und deren verwendung
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
EP1181055A2 (de) 1999-05-14 2002-02-27 Boehringer Ingelheim Pharmaceuticals Inc. Enzym-aktivierte antikrebs prodrugverbindungen
US6552166B1 (en) 1999-10-19 2003-04-22 Merck & Co., Inc. Process for the preparation of conjugates useful in the treatment of prostate cancer
WO2001030804A2 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer

Also Published As

Publication number Publication date
CA2203622C (en) 2011-11-01
NO324045B1 (no) 2007-08-06
ES2297832T3 (es) 2008-05-01
SI0769967T1 (sl) 2008-06-30
EP1880737A1 (de) 2008-01-23
US5962216A (en) 1999-10-05
DE69535665T2 (de) 2009-04-02
AU694546C (en) 2001-09-06
JP4157600B2 (ja) 2008-10-01
EP0769967A1 (de) 1997-05-02
JPH10508291A (ja) 1998-08-18
US20020160943A1 (en) 2002-10-31
US7037898B2 (en) 2006-05-02
US7390629B2 (en) 2008-06-24
NO970748D0 (no) 1997-02-18
US20090137494A1 (en) 2009-05-28
MX9701283A (es) 1997-09-30
US7951772B2 (en) 2011-05-31
WO1996005863A1 (fr) 1996-02-29
US6342480B1 (en) 2002-01-29
DK0769967T3 (da) 2008-03-31
NO970748L (no) 1997-04-10
AU3248695A (en) 1996-03-14
US20060148682A1 (en) 2006-07-06
JP2008069175A (ja) 2008-03-27
NZ291368A (en) 1999-04-29
EP0769967B1 (de) 2007-12-12
PT769967E (pt) 2008-02-18
AU694546B2 (en) 1998-07-23
ATE380559T1 (de) 2007-12-15
CA2203622A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
DE69535665D1 (de) Konjugate enthaltend ein antitumorales mittel und deren verwendung
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
BR0014078A (pt) Inibidores de fator xa
NO20002357D0 (no) Fibrin tetningsmasse eller lim omfattende et hyaluronsyrederivat materiale
IS4328A (is) Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara
ATE360989T1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
TR199700213A2 (xx) 2-Aril s�bstit�entli piridinler.
BR0215397A (pt) Pensos cirúrgicos revestidos
DE69927600D1 (de) Biotechnisch konstruiertes gewebe und verfahren zu dessen produktion und benutzung
DE60031793D1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
DK1100529T4 (da) Thymosin beta 4 fremmer sårheling
BR0008787A (pt) Sistema à base de colágeno injetável para aplicação de células ou agentes terapêuticos
ATE224687T1 (de) Vaginaltampon
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
AU8439998A (en) Compounds
BR9913285A (pt) Método de modulação das células t efetoras da memória e composições
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
ES2187972T3 (es) Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes.
BR9913699A (pt) Composição inseticida
ATE227985T1 (de) Konzentrat für medizinische lösung und dessen verwendung
DK0610698T3 (da) Substituerede imidazo[4,5-b]pyridiner og benzimidazoler som angiotensin II-antagonister
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LA REGION WALLONNE, JAMBES, BE

Owner name: UNIVERSITE CATHOLIQUE DE LOUVAIN, LOUVAIR LA N, BE

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LA REGION WALLONNE, JAMBES, BE

Owner name: UNIVERSITE CATHOLIQUE DE LOUVAIN, LOUVAIN LA N, BE